Hospital
DLP Maria Parham Medical Center LLC
DLP Maria Parham Medical Center LLC was paid $19.09M by Medicaid between Jan 2018 and Dec 2024, across 159 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoDLP MARIA PARHAM MEDICAL CENTER LLC
HENDERSON, NC 27536
HENDERSON, NC 27536
33aNPI1164707725assigned 10/14/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.09M
24GClaims522,622
24DCodes billed159
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#33 of 92
Median peer was paid$11.47M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,737 | $2.30M | |
| 2019 | 91,921 | $2.40M | |
| 2020 | 66,141 | $1.46M | |
| 2021 | 62,086 | $2.41M | |
| 2022 | 70,031 | $3.42M | |
| 2023 | 74,883 | $3.69M | |
| 2024incomplete | 66,823 | $3.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 59,874 | 51,542 | $6.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 25,756 | 21,159 | $2.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 12,206 | 9,760 | $2.19M |
| 41899 | Unlisted procedure, dentoalveolar structures | 6.2% | 1,104 | 1,014 | $1.19M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 839 | 695 | $570K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 7,204 | 6,441 | $558K |
| 71045 | Radiologic examination, chest; single view | 2.8% | 10,902 | 8,833 | $529K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.5% | 3,058 | 2,624 | $486K |
| 87428 | 2.3% | 6,688 | 5,671 | $430K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 2,961 | 2,464 | $405K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 11,850 | 9,931 | $405K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 48,113 | 39,547 | $336K |
147 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 5,475 | $319K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 11,308 | $275K |
| 80053 | Comprehensive metabolic panel | 1.3% | 31,800 | $255K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,206 | $174K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,233 | $155K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,124 | $141K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,242 | $123K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,002 | $114K |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,091 | $112K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,639 | $111K |
| 84484 | <1% | 10,333 | $109K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,352 | $107K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,903 | $106K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,595 | $103K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,084 | $88K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,779 | $74K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,988 | $66K |
| 81001 | <1% | 19,050 | $60K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 31 | $51K |
| 83690 | <1% | 7,739 | $51K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,295 | $48K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,111 | $47K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,208 | $45K |
| 97597 | <1% | 1,145 | $42K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,053 | $40K |
| 81025 | <1% | 4,969 | $38K | |
| J3490 | Unclassified drugs | <1% | 3,580 | $37K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,192 | $37K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,342 | $36K |
| 87480 | <1% | 1,374 | $33K | |
| 82553 | <1% | 4,744 | $29K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 449 | $27K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 254 | $24K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 264 | $23K |
| 83880 | <1% | 877 | $19K | |
| 85610 | <1% | 5,958 | $19K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 535 | $18K |
| 83605 | <1% | 2,337 | $18K | |
| 73562 | <1% | 223 | $17K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 508 | $17K |
| 80299 | <1% | 769 | $16K | |
| 82550 | <1% | 4,904 | $16K | |
| 80069 | <1% | 2,103 | $16K | |
| 59025 | Fetal non-stress test | <1% | 165 | $16K |
| 83735 | <1% | 2,736 | $15K | |
| 87081 | <1% | 2,132 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 565 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,173 | $13K |
| 87510 | <1% | 1,364 | $13K | |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 1,569 | $13K |
| 85730 | <1% | 2,888 | $13K | |
| A9270 | Non-covered item or service | <1% | 22,519 | $13K |
| 70320 | <1% | 259 | $13K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 516 | $12K |
| 80061 | Lipid panel | <1% | 1,037 | $11K |
| 83970 | <1% | 347 | $11K | |
| 87807 | <1% | 826 | $11K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 746 | $11K |
| 86803 | <1% | 574 | $11K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 123 | $10K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 258 | $10K |
| 83021 | <1% | 404 | $10K | |
| 87660 | <1% | 457 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,122 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,331 | $9K |
| 81003 | <1% | 3,146 | $8K | |
| A4618 | Breathing circuits | <1% | 1,138 | $8K |
| 86592 | <1% | 1,593 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 114 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 336 | $8K |
| 86850 | <1% | 768 | $8K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 359 | $8K |
| 87040 | <1% | 1,643 | $8K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 452 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 30 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 210 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 56 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,037 | $6K |
| 82570 | <1% | 1,244 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 294 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 89 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $5K |
| 84550 | <1% | 1,201 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 30 | $5K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 36 | $5K |
| 86787 | <1% | 244 | $5K | |
| 84156 | <1% | 1,235 | $4K | |
| 87340 | <1% | 376 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 434 | $4K |
| 86762 | <1% | 225 | $3K | |
| 11043 | <1% | 68 | $3K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 33 | $3K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 226 | $3K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $3K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 14 | $3K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,018 | $3K |
| 85660 | <1% | 404 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,042 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,223 | $3K |
| 84703 | <1% | 294 | $2K | |
| 86901 | <1% | 759 | $2K | |
| 86900 | <1% | 749 | $2K | |
| 85014 | <1% | 840 | $2K | |
| 85018 | <1% | 840 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 61 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $2K |
| 87186 | <1% | 244 | $2K | |
| 87077 | <1% | 244 | $1K | |
| 82805 | <1% | 57 | $1K | |
| 82950 | <1% | 229 | $1K | |
| 82962 | <1% | 398 | $1K | |
| 80320 | <1% | 59 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 368 | $797.50 |
| 76770 | <1% | 12 | $787.01 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 102 | $784.47 |
| 73630 | <1% | 15 | $700.56 | |
| 82728 | <1% | 63 | $688.63 | |
| 84439 | <1% | 44 | $545.87 | |
| 73130 | <1% | 16 | $461.73 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 254 | $359.48 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $312.21 |
| 83550 | <1% | 40 | $294.66 | |
| 83540 | <1% | 40 | $218.65 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 45 | $190.64 |
| 80076 | <1% | 98 | $171.15 | |
| 84702 | <1% | 13 | $141.70 | |
| 82010 | <1% | 14 | $132.34 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 32 | $107.76 |
| 80143 | <1% | 17 | $97.74 | |
| 85027 | <1% | 14 | $56.05 | |
| 80179 | <1% | 17 | $47.43 | |
| 84520 | <1% | 16 | $41.58 | |
| V2632 | Posterior chamber intraocular lens | <1% | 31 | $37.25 |
| 80051 | <1% | 15 | $34.36 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 71 | $19.34 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 66 | $18.87 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 651 | $17.33 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 57 | $15.53 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 12 | $5.67 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 17 | $2.38 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 196 | $1.62 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 34 | $1.32 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 130 | $0.00 |
| 82565 | 0% | 16 | $0.00 | |
| 97602 | 0% | 21 | $0.00 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 46 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.